Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells

BACKGROUND: BRAF inhibitors are effective anticancer agents in BRAF-mutated melanomas. By contrast, evidences about sensitivity of thyroid carcinomas to BRAF inhibition are conflicting and it has been proposed that BRAF V600E thyroid carcinoma cells are less sensitive to BRAF inhibitors due to activ...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Cell Int
Asıl Yazarlar: Notarangelo, Tiziana, Sisinni, Lorenza, Condelli, Valentina, Landriscina, Matteo
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2017
Konular:
Primary Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5628448/
https://ncbi.nlm.nih.gov/pubmed/29033690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12935-017-0457-z
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller